Role of Cell-Based Therapies in T2D

被引：1

作者：

Ashe, Sudipta ^{[1
]}

Hebrok, Matthias ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
]}

机构：

[1] Univ Calif San Francisco, Diabet Ctr, Dept Med, San Francisco, CA 94143 USA

[2] Tech Univ Munich, TUM Sch Med, Munich, Germany

[3] Tech Univ Munich, Ctr Organoid Syst, Garching, Germany

[4] Helmholtz Zentrum Munchen, Helmholtz Diabet Ctr, Inst Diabet & Obes, Neuherberg, Germany

[5] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Munich, Germany

[6] German Ctr Diabet Res DZD, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany

[7] Helmholtz Munich, Helmholtz Diabet Ctr, Inst Diabet Organoid Technol, Ingolstadter Landstrae 1, D-85764 Neuherberg, Germany

[8] Helmholtz Ctr Munich, Inst Diabet & Organoid Technol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany

[9] Univ Calif San Francisco, Diabet Ctr, 513 Parnassus Ave,HSW 1116,Box 0540, San Francisco, CA 94143 USA

来源：

SEMINARS IN NEPHROLOGY | 2023年 / 43卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Type 2 diabetes mellitus; fi cells; stem cell therapy; immune modulation; Treg therapy; clinical trials; BETA-CELLS; PANCREATIC PROGENITORS; MATURATION; CHALLENGES; GENERATION; REVERSAL;

D O I：

10.1016/j.semnephrol.2023.151432

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes mellitus (T2D) has become a global epidemic affecting the health of millions of people. T2D is a complex and multifactorial metabolic disease, largely characterized by a combination of impaired insulin secretion from fi cells residing within the islets of the pancreas and peripheral insulin resistance. In this article, we discuss the current state and risk factors for T2D, conventional treatment options, and upcoming strategies, including progress in the areas of allogeneic and xenogeneic islet transplantation, with a major focus on stem cell-derived fi cells and associated technologies.

引用

页数：9

共 50 条

[1] T Cell-based Therapies for Atherosclerosis
Ketelhuth, Daniel F. J.
Gistera, Anton
Johansson, Daniel K.
Hansson, Goran K.
CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5850 - 5858
[2] Cell-Based Therapies with T Regulatory Cells
Gliwinski, Mateusz
Iwaszkiewicz-Grzes, Dorota
Trzonkowski, Piotr
BIODRUGS, 2017, 31 (04) : 335 - 347
[3] Lipotoxicity as a Barrier for T Cell-Based Therapies
Boettcher-Loschinski, Romy
Saborido, Judit Rial
Boettcher, Martin
Kahlfuss, Sascha
Mougiakakos, Dimitrios
BIOMOLECULES, 2022, 12 (09)
[4] Cell-Based Therapies with T Regulatory Cells
Mateusz Gliwiński
Dorota Iwaszkiewicz-Grześ
Piotr Trzonkowski
BioDrugs, 2017, 31 : 335 - 347
[5] Regulatory T Cell-based Therapies for Autoimmunity
Arellano, Benjamine
Graber, David J.
Sentman, Charles L.
DISCOVERY MEDICINE, 2016, 22 (119) : 73 - 80
[6] The role of eye banking with cell-based therapies
Tran, Lillian T.
Li, Jennifer Y.
CURRENT OPINION IN OPHTHALMOLOGY, 2023, 34 (04) : 334 - 338
[7] Developing the Quantitative Cell-Based Bioassays for the Discovery and Development of T Cell-Based Therapies
Machleidt, Kara
Grailer, Jamison
Gilden, Julia
Slater, Michael
Stecha, Pete
Hartnett, Jim
Lazar, Dan
Fan, Frank
Cong, Mei
Cheng, Zhijie Jey
MOLECULAR THERAPY, 2021, 29 (04) : 332 - 332
[8] Prospects and Challenges for T Cell-Based Therapies of HCC
Woller, Norman
Engelskircher, Sophie Anna
Wirth, Thomas
Wedemeyer, Heiner
CELLS, 2021, 10 (07)
[9] Cell-based therapies
Sudre, L
Cheung, F
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2005, 86 (03) : A1 - A4
[10] Accelerating R&D of Cell-Based Therapies
Kosovsky, Marshall
GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (17): : 56 - 57

← 1 2 3 4 5 →